1044 / 1983
Klevebro et al. Ann Oncol 2016
N=180
T1N1M0
or
T2-3N0-1M0
AC (73%)
SCC (27%)
Neo-adjuvant chemoradiotherapy:
40 Gy +
Cisplatin 100 mg/m
2
d1 + 5FU 750 mg/m
2
d1-5 x3
RESECTION
Primary endpoint:
Pathologic complete response (pCR)
R
A
N
D
O
M
Neo-adjuvant chemotherapy:
Cisplatin 100 mg/m
2
d1 + 5FU 750 mg/m
2
d1-5 x3
RESECTION
EBRO
2017
Esophageal cancer:
Neo-adjuvant Chemoradiotherapy or Chemotherapy?